RxDoctor Payments Data

Michele Wooten

Nurse Practitioner · Olean, NYNPI 1114299468

Payments from drug & device makers

$8,408in general payments, 2019–2025

Across 438 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$763
  • Lilly USA, LLC$740
  • Sumitomo Pharma America, Inc.$676
  • Novo Nordisk$671
  • Astellas Pharma US Inc$342
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$8,13597%
  • Education$2733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,408 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$58,595
Medicare patients
182
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$165,442
RybelsusSemaglutide49$52,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$51,019
EliquisApixaban61$46,377
JardianceEmpagliflozin53$43,915
VraylarCariprazine Hcl25$37,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$28,332
LinzessLinaclotide33$23,662
XareltoRivaroxaban33$23,633
MounjaroTirzepatide15$20,010
GemtesaVibegron30$17,842
TrulicityDulaglutide15$15,569
FarxigaDapagliflozin Propanediol17$15,337
KerendiaFinerenone21$13,632
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$671$218,139205 claims
AbbVieVraylar, Linzess$763$61,23158 claims
GSKTrelegy Ellipta$313$51,01963 claims
PfizerEliquis$248$46,37761 claims
Boehringer IngelheimJardiance$37$43,91553 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,273$43,66957 claims
Lilly USA, LLCMounjaro, Trulicity$740$35,57930 claims
Johnson & JohnsonXarelto$144$23,63333 claims
Sumitomo Pharma America, Inc.Gemtesa$676$17,84230 claims
BayerKerendia$336$13,63221 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$59$3,168288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Olean

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →